Fifth Third Wealth Advisors LLC Raises Position in Eli Lilly and Company (NYSE:LLY)

Fifth Third Wealth Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 232.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,900 shares of the company’s stock after purchasing an additional 2,028 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,360,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Eli Lilly and Company by 533,336.4% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after purchasing an additional 19,056,108 shares during the period. Norges Bank purchased a new stake in Eli Lilly and Company in the 4th quarter worth $3,416,206,000. Moneta Group Investment Advisors LLC raised its holdings in Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after acquiring an additional 5,440,731 shares during the period. Morgan Stanley raised its holdings in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after acquiring an additional 3,691,436 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in shares of Eli Lilly and Company by 316.9% in the first quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock valued at $217,569,000 after acquiring an additional 1,850,187 shares in the last quarter. 81.38% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 2.5 %

NYSE LLY traded up $13.29 on Friday, hitting $554.77. 1,417,152 shares of the stock were exchanged, compared to its average volume of 2,990,952. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $601.84. The firm has a market capitalization of $526.64 billion, a P/E ratio of 75.38, a P/E/G ratio of 2.19 and a beta of 0.33. The stock has a fifty day moving average price of $539.86 and a two-hundred day moving average price of $459.84.

Want More Great Investing Ideas?

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. The firm had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business earned $1.25 EPS. Research analysts forecast that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research note on Tuesday, August 8th. StockNews.com started coverage on shares of Eli Lilly and Company in a report on Thursday. They issued a “buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $630.00 target price on shares of Eli Lilly and Company in a research note on Monday. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $537.13.

Get Our Latest Report on Eli Lilly and Company

Insider Transactions at Eli Lilly and Company

In related news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the sale, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 591 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $466.62, for a total value of $275,772.42. Following the transaction, the insider now directly owns 101,028,219 shares in the company, valued at approximately $47,141,787,549.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at $4,586,004.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 693,246 shares of company stock worth $20,948,820,977. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.